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ANTIRETROVIRAL THERAPY IN
CHILDREN - INCREASED BENEFIT
FROM INCREASED COMPLEXITY
Antiretroviral therapy (ART) started as monotherapy with
significant short-term gains. With the advent of newer drugs
management has become more complex, but with significant
gains in quality and quantity of life.
The evolution of ART in children lags behind that of adults
for many reasons. These include an unwillingness to use new
medications in children before efficacy has been established
and also difficulty in developing suitable formulations for
children. ART has progressed from monotherapy to dual, triple
and even quadruple therapy, stimulated by insights into the
rapidity of viral replication, development of resistance, and
availability of new agents.
The most pressing concern with ART is its lack of
accessibility to the majority of patients that need it. Other
important issues are how and when to use it in ways that
promote durability of response but avoid unnecessary use.
Most information is derived from studies with relatively short
periods of follow-up. The long-term durability of therapy is not
known, but with development of new agents should be
sustained.
HISTORY
The acquired immunodeficiency syndrome (AIDS) was first
recognised in 1981 after a cluster of 5 adult males presented
with Pneumocystis carinii pneumonia (PCP) in California, USA. 1
One year later, the first report of unexplained
irnmunodeficency in infants appeared. All infants were born to
mothers considered to be at high risk for AIDS and the
possibility of a transmissible agent passing from mother to
child was first postulated.' The first indication that AIDS was
caused by a retrovirus was the discovery of a virus containing
reverse transcriptase by Barre-Sinoussi and colleagues from
lymphoid tissue from a man with the persistent
lymphadenopathy syndrome.3 The retrovirus initially termed
'lymphadenopathy-associated virus' was subsequently
renamed the 'human immunodeficiency virus' (HIV-1) and has
been conclusively shown to be the cause of AIDS.'
lndications for initiating therapy have been formulated by
expert committees, primarily in North America.' In children,
the recommendations for treatment are broadly based and are
updated as soon as new drugs or information become available
(http://www.hivatis.org). Recently the International AIDS
Society published guidelines for ART in Africa. Triple therapy
was recommended, with dual therapy regarded as a less
effective but cheaper alternative. Children in whom ART was
indicated included all those who were symptomatic, especially
where the diagnosis was confirmed early in life, and
asymptomatic children with a CD4 percentage below 25%.
Clinical studies were recommended to identify new patient
groups for therapy'
EFFECT OF ANTIRETROVIRAL THERAPY ON
PROGNOSIS
Many factors influence the prognosis of HIV-1 infection. These
include socio-economic circumstances, since even before ART
became available, outcome varied geographically. For example,
before the use of PCP prophylaxis and ART, Scott and
colleagues showed a median survival period of 38 months
from time of diagnosis in a cohort of perinatally infected
children in Florida.' Eighty per cent presented under the age of
2 years. In contrast, Bobat et al. showed that in Durban 83% of
deaths occurred in infants below 10 months of age, also in the
absence of ART.·
ART has had an enormous beneficial impact on the outcome
of HIV-1 infection in adults with AIDS. Since the introduction
of highly active antiretroviral therapy (HAART) in 1995,
mortality trends have reversed, declining from 30 to 10 per 100
person-years' The impact of HAART on children has been
equally dramatic. De Martino and colleagues recently reported
their observations in 1142 HIV-1-infected children born
between 1980 and 1997. Survival was similar in birth cohorts
from 1980 to 1989 and 1990 through 1995. Thereafter the risk of
death declined by 30% in children receiving two antiretroviral
(ARV) agents and 70% in those receiving triple therapy. ID
MONITORING THE EFFICACY OF
ANTIRETROVIRAL AGENTS
Measuring of CD4+ T-cell counts and percentages and, more
recently, plasma HIV-1 RNA are essential for monitoring the
success .of therapy. In paediatric care, attention should also be
given to the maintenance of continued growth and
development. From the outset, ART studies in children have
included evaluation of these parametersU .13
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MONOTHERAPY VERSUS DUAL THERAPY
The elucidation of the life cycle of HIV and the characterisation
of proteins involved in entry and key enzymatic steps have
assisted the development of ARV agents. Zidovudine (ZDV), a
nucleoside reverse transcriptase inhibitor (NRTI), was initially
synthesised as an anti-cancer drug. It has been used clinically
since the successful conclusion of a 6-month placebo-<:ontrolled
trial in which it was associated with a dramatic difference in
mortality in adults (1 of 143 v. 19 of 137).14 This study was
terminated early. Regrettably, the benefits were not durable and
a clinical trial lasting 3 years showed no survival or morbidity
benefits. ls
The first paediatric study began shortly after the conclusion
of the adult placebo-controlled study and was published in
1988. Pizzo et al. studied continuously administered ZDV in 21
symptomatic children, 13 of whom had encephalopathy. All
patients with encephalopathy showed improvement.u Two
years later, a large multicenter study confirmed the efficacy of
oral ZDV in children with advanced HIV disease. The maximal
duration of follow-up was 90 weeks. 13
The next step was to compare specific ARV agents. Englund
et al. compared ZDV to either didanosine (ddl) or combined
therapy in 831 children.I. At a median follow-up period of 23
months, the ZDV arm was discontinued as it was associated
with a significantly increased risk of disease progression
compared with combined therapy. By the end of the study
(median duration of follow-up 32 months) ddl monotherapy
was equivalent to combined therapy both for mortality and
disease progression.I. A second study, however, showed that
ddI monotherapy was inferior to dual therapy consisting of
ZDV with either ddI or lamivudine. lI After a median follow-up
period of 9 months, there were 38 (16%) failures on ddl versus
15 (6.4%) on ZDV plus lamivudine.
Other dual therapy regimens have also shown efficacy. The
combination of ddI and stavudine, in particular, has been
associated with a durable but incomplete virological response
in children followed up for 48 weeks. It was associated with a
0.5 log (5-fold) reduction in plasma HIV RNA at week 12 that
was maintained through week 48.17 Data presented at the recent
AIDS Conference in Durban showed that 7 of 16 children with
mild disease (plasma HIV RNA below 50 000 copies per ml)
actually achieved maximal suppression of viral replication.
A contentious issue in the South African context is whether
monotherapy should be attempted in circumstances where
both dual and triple therapy are unaffordable. While a family
I IEII income might cope with a monthly expenditure of R200,
I doubling this amount is often beyond reach. We have recently
shown that monotherapy can have significant short-term
benefits in symptomatic children with a history of frequent or
long hospitalisation for intercurrent disease.ls The limitations of
monotherapy should be understood, especially the
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development of resistance, which might compromise
therapeutic options should ART become more accessible.
TRIPLE THERAPY
The addition of either a protease inhibitor (PI) or a non-
nucleoside reverse transcriptase inhibitor (NNRTI) to dual
NRTI therapy has had a major positive impact in children.
Initial studies suggested that infants and children might have
lower response rates than adults receiving triple tilerapy.
Whereas between 43% and 75% of adults might be expected to
respond with plasma HIV RNA below the limits of
detectability, initial observations suggested that only 25 - 40%
of children responded in this way. I' Supporting this
observation is the excessively high plasma HIV RNA levels
found in children especially in the first few years of life.'"
Recent studies, however, have shown that if strict attention is
given to compliance and adequate medication is given, therapy
may be extremely successful. For example, Van Rossum et at.
demonstrated in a multi-centred Dutch study that 70% of
children had less than 500 RNA copies per rnl of plasma and
48% had less than 40 copies per rnl after 6 months' follow-up.'1
The PI used was indinavir, which is available only in capsule
form and necessitated 8-hourly administration, and was
combined with ZDV and lamivudine. The dosage of indinavir
needed to be increased in 70% of children following results of
pharmacokinetic studies. The difficulty in maintaining
adherence cannot be overemphasised. As an illustration of the
intensity of supervision, in Van Rossum's study of 28 children,
37 investigators are listed. Even though 15 children had
previously been treated with ZDV; an excellent virological
response was seen in all those who were compliant.
The use of drugs with long half-lives, permitting once-daily
dosing, may contribute towards successful virological
suppression. Efavirenz, an NNRTI, together with nelfinavir, a
PI and one or more NRTIs was associated with plasma RNA
below 400 copies per rnl in 76% of children and less than 50
copies per rnl in 63% after 48 weeks.22
CLINICAL RESPONSE IN THE PRESENCE OF
INADEQUATE SUPPRESSION OF VIRAL
REPLICATION
Non-adherence is common and is associated with a poor
virological response. Adherent patients may have a sustained
but incomplete response. Although it is likely that treatment
may ultimately fail due to development of resistance, patients
may continue to derive benefit from substandard therapy. For
example, Watson studied 72 children on HAART of whom 42
were adherent (defined by filling 75% of prescriptions) and 29
non-adherent. Fifty-eight per cent of adherent patients but only
3 of 29 non-adherent patients achieved a plasma HIV-RNA •
level below 400 copies per ml. The ages of patients ranged from
3 months to 12 years and the median duration of follow-up
was 282 days. There were no deaths in this study, even in the
non-adherent patients."
A discordance between virological and CD4+ T-cell response
has been observed in children receiving PIs. In a prospective
study of 25 children, 22 of whom had prior exposure to NRTIs
and NI'-TRTIs, only 5 had sustained suppression of plasma HlV
RNA, yet 22 had sustained elevations of CD4+ T cells. All had
advanced disease with CD4+ T-cell percentages below 6% at
baseline. Median duration of follow-up was 18.8 months."
A reasonable conclusion from these two studies is that it may
be worth persisting with 'failing' PI-containing regimens as
long as there is a beneficial CD4+ T-cell response. There are few
data on the appropriate response to patients in whom NRTI
therapy fails. Probably, especially if few options are available, it
is better to persist with a failing regimen than discontinue it,
but clinical judgement should be exercised. Both ZDV and
lamivudine have been associated with resistance mutations
that diminish viral replicative capacity.2526
TREATMENT OF PRIMARY INFECTION
Progression of HlV disease is associated with ongoing
destruction of CD4+ T cells and gradual loss of the
immunological repertoire. In a landmark study of the
prognostic value of plasma HlV RNA in adults, even a level
below 4 500 copies per ml was associated with an 8% risk of
developing the acquired immunodeficiency syndrome or death
within 5 years. 27 HlV infection may therefore be associated with
serious morbidity even in the absence of excessive viral
replication.
Because the majority of paediatric infections occur during
delivery," it is possible to completely suppress viral replication
through early and aggressive therapy as soon as infection is
detected and so maintain all intact immunological system.
Luzuriaga and colleagues recently reported on 17 HlV-1-
infected infants in whom either three or four drugs were
initiated between 15 days and 3 months of age. All had
sustained suppression of plasma HlV-1 RNA to below 50
copies per ml but continued presence of proviral DNA on
follow-up ranged between 16 and 56 months. All had intact
immune systems as evidenced by their ability to respond
appropriately to various antigenic challenges.'"
ANTIRETROVIRAL-EXPERIENCED CHILDREN IN
WHOM THERAPY FAILS
The term 'salvage therapy' has been adopted for heavily
treated patients in whom ART has failed. For this group of
patients there are a number of options. By changing to three
previously unused ARVs, one increases the chances of a
favourable response.'" Genotyping assays have been developed
to assist with drug selection by screening for known mutations
already associated with drug resistance. Preliminary experience
in children supports the use of this assay in ARV-experienced
children."
A ROLE FOR HYDROXYUREA?
The cytostatic agent hydroxyurea (HU), used previously for
chronic myelogenous leukaemia and other lyrnphoproliferative
syndromes, may augment dd!. Long-term use of HU and ddI
in adults has recently been reported on. Sustained but
incomplete suppression of viral replication occurred in 12
adults after more than 24 months of therapy. Initially the
median plasma HlV-RNA was 51 795 copies per ml and CD4+
T-cell count 376 cells/mm'. By week 122, the plasma HlV-RNA
had declined by 2.2 log 10 of virus and the CD4+ T-cell count
had increased by an average of 30 cells'2
There are only limited data in children. Kline and colleagues
performed a phase I study in 16 children who were already
receiving either single or dual NRTI therapy (stavudine plus
ddI, stavudine alone or stavudine plus lamivudine). A dosage
of 30 mg/kg/d of HlV was established. Five children had a
decrease of 0.5 log 10 of plasma RNA by week 4.33
Avila Figuerroa recently presented an analysis of 21 children
between 2 and 8 years of age receiving ddI + D4T and HU (30
mg/kg/d) for 9 months. The mean decline in plasma HlV-
RNA was 1.1 log. The incidence of serious infections requiring
hospitalisation declined from 3.6 to 1.2 per person-year and
furthermore adverse events were negligible." The precise role
of HU as a therapeutic option still remains uncertain and in
addition there remain concerns regarding side-effects, namely
pancreatitis, neoplasms and possible infertility.
COST-EFFICACY - THE COST OF NOT TREATING
CHILDREN
Cost-efficacy analyses have mainly concentrated on the
overwhelming benefits of introducing an effective programme
to reduce mother-to-child transmission. For example,
Wilkinson et al. have recently calculated that a national
programme preventing only 37% of expected paediatric
infections will be costceffective.35 A recent study from Abidjan
showed that the cost of caring for an HlV-infected child for a
year was RI 530, 1.7 times more than for an HlV-exposed,
uninfected child.36
There is a paucity of data on the cost-efficacy of treating
HlV-1-infected children with ART. In South African hospitals a
large amount is currently spent on palliative care for
hospitalised children. The costs to the parents in terms of
income loss and transport are unknown, but are likely to be
substantial. At Tygerberg Hospital, approximately RI million
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per year has been spent on palliative care for the last 3 years.
The average daily cost of medication, food and expendable
equipment is approximately R345 (K Muller - personal
communication), which is almost sufficient for 1 month of dual
[RTI therapy.
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